A Potential Strategy for Treating Parkinson's Disease Through Intranasal Nanoemulsions

Area of Science:

• Pharmaceutical Sciences
• Neuroscience
• Biotechnology

Background:

• Intranasal delivery offers a direct pathway to the central nervous system, bypassing the blood-brain barrier.
• Nanotechnology, specifically nanoemulsions, presents an innovative strategy for enhanced nose-to-brain drug delivery.
• Mucoadhesive nanoemulsions prolong drug accumulation and targeted delivery, crucial for treating neurological disorders.

Purpose of the Study:

• To review the application of nanoemulsion-based intranasal drug delivery systems for neurodegenerative disorders.
• To explore the role of nanoemulsion formulation components and globule size in brain targeting.
• To discuss the potential of nanoemulsions in treating Parkinson's disease.

Main Methods:

• Review of existing literature on intranasal drug delivery and nanoemulsion technology.
• Analysis of nanoemulsion formulation parameters (oil, surfactant, co-surfactant) affecting surface tension and particle coalescence.
• Examination of globule size and zeta potential requirements for effective brain permeation.

Main Results:

• Nanoemulsion formulations with globule size < 200 nm are optimal for brain permeation, considering human axon dimensions.
• Mucoadhesive properties of nanoemulsions enhance drug residence time in the nasal cavity.
• Modified nanoemulsion systems like nanogels and in-situ gels show significant advantages for neurodegenerative disorder treatment.

Conclusions:

• Intranasal nanoemulsions are a viable and effective strategy for nose-to-brain drug delivery, particularly for neurodegenerative diseases like Parkinson's.
• Optimizing nanoemulsion characteristics, such as globule size, is critical for successful brain targeting.
• Further research into advanced nanoemulsion formulations holds significant promise for future neurological therapies.